min qing

Clinical biomarker and companion diagnostic

Responsibilities: • Provide best-in-class and on-time bioanalytics and biomarker support to clinical projects in China and in Asian Pacific • Implement translational research to support increased demand for discovery phases of the pipeline. • Provide support in the partnerships to improve and facilitate processes. • Provide support to China Business Development and Medical Affairs. Project/Achievements: 1. As study director, develop different type of NGS mutation assay, gene expression assay and IHC assay to identify specific biomarkers (EGFR/Her2/Her3/Her4, RAS, cMet, integrins, cytokines and hypoxia markers) for drug personalized therapy. Ensure that the bioanalysis assays performed at Merck Serono China GED Lab, if deem necessary, following the GLP Principles. In addition, communicated with finance and vendors to make the budget and arranged reagents and clinical/preclinical sample delivery before initiation of the projects. 2. As study monitor, performed due diligence and identified the correct CRO to perform sample analysis; Reviewed and approved study plan, study reports and raw data to ensure data accuracy. Completed the assay method validation and sample analysis on time and within budget successfully. - Problem solving in data analysis to improve data quality. - Troubleshooting in sample analysis to improve data reliability - Finalize the acceptance criteria. 3. Worked closely and effectively with Global project team on NGS mutation data analysis, data mining, gene expression analysis, IHC scoring and evaluation as well as preparation of study plan and study report. 4. Due diligence effort on Erbitux and PD-L1 collaborations with KOLs.

Got biochemical assay results for cmpd profiling. Biochemical Assay development and optimization.; 1. Got biochemical assay result for weekly compound (LCMS) with high efficient and quality to support the team. 2. MOA study of HMT and HDM inhibitors (Peptide and SAM-Competition assay, detail study, quick dilution assay and cmpds in Enzyme progress curve test); 3. Development of HTRF assay and coupled assay to support MOA study of interesting cmpds and for HTS; 4. Development of new methylase and demethylase LCMS assays. 5. Extensive experience on data analysis tools such as Excel, Prism, Spotfire, Helios.;

Responsibilities:  Responsible for developing HTS assays for Drug Discovery Unit, supporting other groups in Disease Biology Unit for antiviral mechanism of HTS hits.  Write up the SOPs for developed assays.  Take part in and implement projects in Group. Special Skills and Competence Experience with molecular and cellular biology. 1. Construction of DENV infectious clone and DENV-Replicon. 2. Construction and establishment of flavivirus viral like particles system for diagnosis and HTS. 3. Reporter-harboring replicon cell line selection 4. Analysis of RNA –protein, protein-protein interaction by Co-immunoprecipitation (Co-IP), RT-PCR, western blot, Fluorescence spectroscopy and IFA (Confocal microscope). 5. Experience with protein purification using HPLC. 6. Experience with culture of BHK-21, Vero, LLCMK-2, Huh-7, Huh-7.5, A549, 293T and C6/36 cells (Electroporation of infectious RNA to these cell lines and monitor the RNA copies and renilla luciferase activity by Real-time RT- PCR and luminescence signal) 7. Identify host proteins involved in dengue infection by SiRNA approach in A549 cells and Huh-7.5 cells. 8. Determination of virus titer by plaque assay on Vero cells and BHK-21 cells. 9. Selection of escape mutant virus on Vero cells and BHK-21 cells. Experience in drug discovery in biology side. 1. Development of reporting replicon cell-based HTS assay for drug discovery. 2. Virus-like particles assay for compounds high-throughput screening in different cell line. 3. TSV01 Reporting virus for compounds high-throughput screening in different cell line. 4. Familiar with Cytotoxicity assays: Tested by MTT or Cell-titer Glo. 5. Good at spoken and written English. 6. Be enthusiastic in science and independent in developing research programs.

1. 2008/03-2008/08: Evaluation of the anti-flavivirus virus effects of cyclophilin inhibitors (Cyclosporine). 1. A panel of CyP knockdown cell lines by shRNA were used to examine the role of CyP on flavivirus replication by flavivirus VLP assay and viral reduction assay. 2. Co-IP, RT-PCR, recombinant CyPA production, GST binding assay and western blot to examined whether CyPA directly interacts with viral NS5 in the replication complexes. 3. MTS assay to test cytotoxicity of cyclosporine on vero and Huh7.5 cell line. 4. Identification of mode of action of cyclosporine by viral reduction assay, time-of-addition, WNV and DENV-1 replicon cell line and transient replicon assay. 5. Biochemical analysis showed that cyclosporine could directly suppress The interaction between CyPA and flavivirus NS5 protein. 2. 2008/03-2008/08: Construction of VEEV-PAC2A-DENV/WNV-CprME BHK-21 cell line. 3. 2008/01-2008/08: A Virus-type Specific Serological Diagnosis of Flavivirus Infection Using Virus-like Particles 1. Production of infectious VLPs for a panel of flaviviruses. 2. Stability of luciferase gene in WNV VLP by RT-PCR. 3. Development of VLP-based neutralization assay. 4. Development of a virus-type specific diagnosis of WNV infection using flavivirus VLPs.